jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Stomach biopsy - Large Biopsy 3-6 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Histology of stomach tissue.

₹666₹951

30% OFF

Stomach Biopsy - Large Biopsy 3-6 cm

  • Why is it done?
    • A stomach biopsy involves removing tissue samples (3-6 cm) from the stomach lining for microscopic examination to diagnose various gastric conditions and detect abnormalities
    • Primary Indications: Detection of Helicobacter pylori (H. pylori) infection; Evaluation of chronic gastritis; Investigation of gastric ulcers; Diagnosis of gastric cancer and malignancies; Assessment of Barrett's esophagus complications; Evaluation of suspicious gastric lesions or masses; Investigation of chronic abdominal pain of unknown etiology; Diagnosis of autoimmune gastritis; Assessment of intestinal metaplasia; Evaluation of gastric polyps
    • Typical Timing: Performed during upper endoscopy (esophagogastroduodenoscopy/EGD); Usually done when endoscopy reveals abnormal mucosal findings; May be performed as part of comprehensive screening in high-risk patients; Often indicated when symptoms persist despite initial diagnostic workup
  • Normal Range
    • Normal Findings: Intact gastric mucosa with normal glandular structure; Absence of H. pylori organisms; No dysplasia or malignant cells; Normal inflammatory cell infiltration (minimal or absent); Appropriate mucosal thickness and architecture; No intestinal metaplasia; Absence of special organisms or inclusions
    • Result Interpretation: • Negative Result: No pathologic findings; Normal histology; Absence of infection or malignancy • Positive Result: Presence of significant pathology; Detection of organisms, dysplasia, or malignancy; Evidence of specific disease process • Units: Histopathologic examination; Size of specimen: 3-6 cm; Qualitative assessment with descriptive pathology report
  • Interpretation
    • Detailed Interpretation of Results:
    • H. pylori Positive: Indicates active bacterial infection; Requires eradication therapy; Associated with increased gastritis risk and ulcer development; Treatment recommended to prevent complications
    • Chronic Gastritis: Inflammation of stomach lining; May indicate H. pylori infection or autoimmune gastritis; Requires identification of underlying cause; Risk factor for atrophic changes and gastric cancer
    • Intestinal Metaplasia: Replacement of normal gastric mucosa with intestinal-type epithelium; Premalignant condition; Associated with increased gastric cancer risk; Requires surveillance and lifestyle modifications
    • Dysplasia Detected: • Low-grade dysplasia (LGD): Risk of progression to high-grade dysplasia or cancer; Requires close endoscopic surveillance every 6-12 months • High-grade dysplasia (HGD): Significant cancer risk; May warrant endoscopic therapy or surgical intervention; Requires expert consultation
    • Gastric Cancer/Malignancy: Presence of malignant cells indicates gastric carcinoma; Requires staging studies (CT, EUS); Urgent consultation with oncology and surgery; Treatment planning based on cancer type and stage
    • Autoimmune Gastritis: Presence of parietal cell antibodies; Atrophic mucosa with loss of acid-producing cells; Risk of vitamin B12 deficiency and pernicious anemia; Requires long-term monitoring and B12 supplementation
    • Factors Affecting Interpretation: Biopsy location and size (3-6 cm allows comprehensive sampling); Recent antibiotic or PPI use may affect H. pylori detection; Adequate tissue fixation and processing; Pathologist expertise in gastric pathology; Number and distribution of biopsies obtained
  • Associated Organs
    • Primary Organ System: Gastrointestinal tract; Stomach (fundus, body, antrum); Associated structures: esophagus, pylorus, duodenum
    • Conditions Associated with Abnormal Results: Helicobacter pylori infection; Peptic ulcer disease; Gastritis (acute and chronic); Gastric cancer; Gastric polyps; Barrett's esophagus with gastric involvement; Pernicious anemia (autoimmune gastritis); Lymphoma (gastric MALT lymphoma); Zollinger-Ellison syndrome; Bile reflux gastritis
    • Diseases Diagnosed/Monitored: Adenocarcinoma of stomach; Gastric neuroendocrine tumors; Intestinal metaplasia; Dysplastic lesions; Infectious gastritis; Chemotherapy-induced changes; Radiation-induced injury; Crohn's disease involvement of stomach
    • Potential Complications of Abnormal Results: Gastric hemorrhage from erosive disease; Perforation in advanced malignancy; Malabsorption and nutritional deficiencies; Progression to gastric cancer if dysplasia untreated; Severe anemia from chronic bleeding; Gastric outlet obstruction from malignancy; Metastatic disease spread; Peritoneal involvement; Death from advanced gastric cancer if untreated
  • Follow-up Tests
    • Based on H. pylori Positive Results: Urea breath test or stool antigen test (post-treatment confirmation); Serology for H. pylori antibodies; Testing for antibiotic resistance; Repeat endoscopy after eradication therapy completion; Surveillance for treatment success at 4-6 weeks post-therapy
    • For Dysplasia/Premalignant Findings: Repeat endoscopy with targeted biopsies in 6-12 months; Endoscopic ultrasound (EUS); Chromoendoscopy for enhanced visualization; CT or MRI staging if malignancy suspected; Multifocal biopsies of any visible lesions; Consider endoscopic therapy for high-grade dysplasia
    • For Gastric Cancer Diagnosis: CT chest/abdomen/pelvis for staging; Endoscopic ultrasound (EUS) for depth and lymph node assessment; PET-CT for metastatic disease evaluation; Tumor marker studies (CEA, CA 19-9); Molecular testing for HER2 status and MSI/dMMR; Surgical consultation for staging and treatment planning
    • For Autoimmune Gastritis: Vitamin B12 and folate levels; Intrinsic factor and parietal cell antibodies; Complete blood count for pernicious anemia; Periodic monitoring for progression; Thyroid function tests; Endoscopic surveillance every 3-5 years
    • Complementary/Related Tests: Small bowel imaging (capsule endoscopy); Upper GI series with barium; Immunohistochemistry for special staining; Flow cytometry for lymphoid lesions; Molecular testing for specific mutations; Serology for other autoimmune conditions
  • Fasting Required?
    • Fasting Required: YES
    • Fasting Duration: NPO (nothing by mouth) for minimum 6-8 hours before procedure; Preferably overnight fast (10-12 hours) recommended
    • Special Instructions: No solid food after midnight before procedure; Clear liquids may be permitted up to 2-4 hours prior (follow specific facility instructions); No gum or candy; Arrive with empty stomach for optimal visualization; Confirm pre-procedure instructions with endoscopy facility
    • Medications to Avoid: Proton pump inhibitors (PPIs) - stop 7-14 days before if testing for H. pylori; H2-receptor antagonists - discontinue 24-48 hours prior; Antibiotics - avoid for 4 weeks before H. pylori testing; NSAIDs - discontinue 1 week before if possible; Bismuth compounds - avoid for 4 weeks pre-procedure; Aspirin and blood thinners - consult with physician regarding continuation; Take regular morning medications with small sip of water per facility guidelines
    • Additional Patient Preparation: Arrange transportation as sedation will be used (patient cannot drive); Obtain informed consent discussing risks and benefits; Report allergies and previous adverse reactions; Provide complete medical and medication history; Discuss sedation options with anesthesia; Sign procedure consent forms; Wear loose, comfortable clothing; Remove dentures, jewelry, and valuables; Empty bladder before procedure; Establish IV access per facility protocol; Expected recovery time 1-2 hours after sedation; Have responsible adult available for discharge

How our test process works!

customers
customers